Alpha Cognition Inc

Alpha Cognition Inc. is a biopharmaceutical company that develops treatments for patients with neurodegenerative diseases in the United States and Canada. Its commercial development program includes ZUNVEYL, an oral tablet formulation for treating Alzheimer's disease. Pre-clinical programs include ZUNVEYL in combination with memantine for moderate-to-severe Alzheimer's disease, ALPHA-1062 sublingual and intranasal formulations for cognitive impairment with mild traumatic brain injury, and the ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for neurodegenerative diseases such as amyotrophic lateral sclerosis and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Grapevine, Texas.